Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levelsMilan J. Sonneveld, Benjamin Maasoumy, André Boonstra et al.|Journal of Hepatology|2022Cited by 121
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J. Sonneveld, Benjamin Maasoumy, Teerha Piratvisuth et al.|Clinical Gastroenterology and Hepatology|2020Cited by 103
Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling studyMathias Jachs, Mattias Mandorfer, Juan Carlos García‐Pagán et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 69
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis—A real-world case seriesChristopher Dietz-Fricke, Pietro Lampertico, Julia M. Grottenthaler et al.|Hepatology|2024Cited by 36
HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral TherapyMilan J. Sonneveld, Benjamin Maasoumy, André Boonstra et al.|Gastroenterology|2023Cited by 23